Suppression of azoxymethane-induced colon cancer development in rats by a prostaglandin E receptor EP1-selective antagonist

Cancer Science

Volumn 96, Issue 5, 2005, Pages 260-264

  Niho, Naoko ^a   Mutoh, Michihiro ^a   Kitamura, Tomohiro ^a   Takahashi, Mami ^a   Sato, Hidetaka ^b   Yamamoto, Hiroshi ^c   Maruyama, Takayuki ^c   Ohuchida, Shuichi ^c   Sugimura, Takashi ^a   Wakabayashi, Keiji ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b JAPAN FOOD RESEARCH LABORATORIES   (Japan)

^c ONO PHARMACEUTICAL CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 [3 (4 CHLORO 2 METHYLPHENYLSULFONYLAMINOMETHYL)BICYCLO[2.2.2]OCTAN 2 YL] 5 HEXENOIC ACID; AZOXYMETHANE; BROXURIDINE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E1; RECEPTOR SUBTYPE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CANCER SIZE; COLON ADENOCARCINOMA; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; DIET; DRUG MECHANISM; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; RAT; TREATMENT OUTCOME;

ANIMALS; APOPTOSIS; AZOXYMETHANE; BICYCLO COMPOUNDS; COLONIC NEOPLASMS; HEXANOIC ACIDS; MALE; RATS; RATS, INBRED F344; RECEPTORS, PROSTAGLANDIN E;

EID: 21244453953     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2005.00047.x     Document Type: Article

References (29)

1. Stewart BW, Kleihues P, eds. World Cancer Report. Lyon: IARC Press, 2003; 12-17.
2. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-6.
3. Rao CV, Rivenson A, Simi B, Zang E, Kelloff G, Steele V, Reddy BS. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995; 55: 1464-7.
4. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997; 39: 1-20.
5. Chan AT. Aspirin, non-steroidal anti-inflammatory drugs and colorectal neoplasia: future challenges in chemoprevention. Cancer Causes Control 2003; 14: 413-18.
6. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120.
7. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O, Langenbach R. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000; 60: 4705-8.
8. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993; 122: 518-23.
9. 2. Gut 1994; 35: 675-8.
10. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994; 46: 205-29.
11. Suda M, Tanaka K, Natsui K, Usui T, Tanaka I, Fukushima M, Shigeno C, Konishi J, Narumiya S, Ichikawa A, Nakao N. Prostaglandin E receptor subtypes in mouse osteoblastic cell line. Endocrinology 1996; 137: 1698-705.
12. Ushikubi F, Hirata M, Narumiya S. Molecular biology of prostanoid receptors; an overview. J Lipid Mediat Cell Signal 1995; 12: 343-59.
13. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79: 1193-226.
14. 1 in colon carcinogenesis. Cancer Res 1999; 59: 5093-6.
15. 4 in colon carcinogenesis. Cancer Res 2002; 62: 28-32.
16. Δ716 knockout mice. Nature Med 2001; 7: 1048-51.
17. 3 during colon cancer development. Gut 2004; 53: 1151-8.
18. 1 antagonist for potential properties in colon carcinogenesis. Anticancer Res 2001; 21: 3865-9.
19. 1 selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice. Cancer Lett 2000; 156: 57-61.
20. 4 antagonists on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Cancer Sci 2000; 94: 618-21.
21. 1 antagonist, on breast cancer development. Carcinogenesis 2001; 22: 2001-4.
22. Rao CV, Indranie C, Simi B, Manning PT, Connor JR, Reddy BS. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 2002; 62: 165-70.
23. Pozharisski KM. Tumors of the intestines. In: Turusov VS, ed. Pathology of Tumours in Laboratory Animals. Lyon: IARC Scientific Publications, 1990; 119-40.
24. Verstovsek G, Byrd A, Frey MR, Petrelli NJ, Black JD. Colonocyte differentiation is associated with increased expression and altered distribution of protein kinase C isozymes. Gastroenterology 1998; 115: 75-85.
25. Diaz-Meco MT, Berra E, Municio MM, Sanz L, Lozano J, Dominguez I, Diaz-Golpe V, Lain de Lera MT, Alcami J, Paya CV et al. A dominant negative protein kinase C ζ subspecies blocks NF-κB activation. Mol Cell Biol 1993; 13: 4770-5.
26. kip1 and hypophosphorylation of the retinoblastoma protein in intestinal epithelial cells. J Biol Chem 1997; 272: 9424-35.
27. Borner C, Ueffing M, Jaken S, Parker PJ, Weinstein IB. Two closely related isoforms of protein kinase C produce reciprocal effects on the growth of rat fibroblasts. Possible molecular mechanisms. J Biol Chem 1995; 270: 78-86.
28. Scaglione-Sewell B, Abraham C, Bissonnette M, Skarosi SF, Hart J, Davidson NO, Wali RK, Davis BH, Sitrin M, Brasitus TA. Decreased PKCα expression increases cellular proliferation, decreases differentiation, and enhances the transformed phenotype of CaCo-2 cells. Cancer Res 1998; 58: 1074-81.
29. II expression in rat colon: modulation by diet and relation to in situ cell proliferation and apoptosis. Carcinogenesis 2000; 21: 1513-19.